SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.

Christoph RochlitzMartin BiglerRoger von MoosJürg BernhardKlazien Matter-WalstraAndreas WickiKhalil ZamanSandro AnchisiMarc KüngKyung-Jae NaDaniela BärtschiMarkus BornerTamara RordorfDaniel RauchAndreas MüllerThomas RuhstallerMarcus VetterAndreas TrojanUrsula Hasler-StrubRichard CathomasRalph Winterhaldernull null

Published in: BMC cancer (2016)

This trial failed to meet its primary endpoint of a reduced rate of prespecified grade 3-5 AEs with metronomic bevacizumab, cyclophosphamide and capecitabine.

Keyphrases

phase iii
open label
double blind
placebo controlled
metastatic colorectal cancer
clinical trial
phase ii
phase ii study
high dose
low dose
study protocol
bone marrow
radiation therapy
chemotherapy induced